Superworth

Palisade Bio revenue PALI

Sales by quarter and over the last twelve months, from 2011.

Last 12 months, to Jun 30, 2026
n/m
a quarter missing
Latest quarter, Q2 FY26
$500K
Fiscal year 2024
$0
−100% on the year before

Palisade Bio's twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q2 FY26, it was $500K.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2024$0−100%
FY2023$250Kn/a
FY2022$0−100%
FY2020$13.5K−12%
FY2019$15.4K−94%
FY2018$260K+0%
FY2017$260K+1500%
FY2016$16.2K+56%
FY2015$10.4K−45%
FY2014$18.8K−83%
FY2013$110K−73%
FY2012$407.7Kn/a
FY2011n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$500Kn/an/a
Q2 FY25$0n/an/a
Q4 FY24$0n/a$0
Q3 FY24$0n/a$0
Q2 FY24$0n/a$0
Q1 FY24$0−100%$0
Q4 FY23$0n/a$250K
Q3 FY23$0n/a$250K
Q2 FY23$0n/a$250K
Q1 FY23$250Kn/a$250K
Q4 FY22$0n/a$0
Q3 FY22$0n/an/a

Against its peers

Companies in Biotechnology nearest Palisade Bio's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
PALIPalisade Bion/m
PLXProtalix BioTherapeutics$80.6M+30% a year
MGTXMeiraGTx$397.5M
VCELVericel$306.3M+23% a year
Peer median$306.3M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Palisade Bio

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.